1167 (1167) Fair Value & Analysis

Healthcare · Market cap HK$3.7B

1 1167 1167 · HK

PriceHK$4.78

Fair ValueHK$0.6900

Upside-85.6%

Quality43/100

Evidence: Low Range HK$0.4500 – HK$0.8600

Fair value as of: Jul 2, 2026

From 3 valuation models · updated today

Share price −2.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$4.12 – HK$11.60 · fair‑value band HK$0.4500 – HK$0.8600 · the HK$4.78 price screens above the HK$0.6900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1167 (1167) currently trades at HK$4.78, while our model-based Fair Value estimate is HK$0.6900 — implying the stock looks roughly 85.6% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at HK$53.5M. It earns a return on equity of -17.2%. The balance sheet holds a net cash position of HK$778M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$53.5M

Revenue growth (YoY) -95.0%

Net margin -273%

Return on equity -17.2%

Free cash flow −HK$187M FY2025

Operating margin -1,292%

More key figures

EPS (TTM) HK$-0.0800

Net cash HK$778M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1167 reported revenue of HK$52.1M in FY2025 versus HK$153M in FY2021, a compound −23.6%/yr. Reported net income was −HK$142M in FY2025.

Revenue −23.6%/yr

FY21 HK$153M

FY22 HK$95.7M

FY23 HK$63.5M

FY24 HK$156M

FY25 HK$52.1M

Net income

FY21 −HK$301M

FY22 −HK$372M

FY23 −HK$359M

FY24 −HK$156M

FY25 −HK$142M

Is 1167 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	449.62 MXN	-94%
Regeneron Pharmaceuticals, Inc REGN	$601.65	$577.20	-4%
UCB SA UCB	€251.70	€180.06	-28%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$288.18	$51.70	-82%
Samsung Biologics Co 207940	1,000,000 KRW	724,332 KRW	-28%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1167 (1167) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.6900 versus a price of HK$4.78 — about −86% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1167?

Our model-based fair value for 1167 is HK$0.6900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$4.78.

What is the quality score of 1167?

1167 has a Quality Score of 43/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1167 (1167)?

1167 reported trailing-twelve-month revenue of about HK$53.5M (latest available figure, as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.